GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » EPS (Diluted)

Albireo Pharma (FRA:BDQM) EPS (Diluted) : €-6.36 (TTM As of Sep. 2022)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma EPS (Diluted)?

Albireo Pharma's Earnings per Share (Diluted) for the three months ended in Sep. 2022 was €-1.94. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 was €-6.36.

Albireo Pharma's EPS (Basic) for the three months ended in Sep. 2022 was €-1.94. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2022 was €-6.36.

Albireo Pharma's EPS without NRI for the three months ended in Sep. 2022 was €-1.94. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2022 was €-6.36.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.


Albireo Pharma EPS (Diluted) Historical Data

The historical data trend for Albireo Pharma's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albireo Pharma EPS (Diluted) Chart

Albireo Pharma Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Dec17 Dec18 Dec19 Dec20 Dec21
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.64 -3.46 -4.54 -5.53 -1.57

Albireo Pharma Quarterly Data
Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.47 -0.50 -1.99 -1.93 -1.94

Competitive Comparison of Albireo Pharma's EPS (Diluted)

For the Biotechnology subindustry, Albireo Pharma's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albireo Pharma's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albireo Pharma's PE Ratio distribution charts can be found below:

* The bar in red indicates where Albireo Pharma's PE Ratio falls into.



Albireo Pharma EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Albireo Pharma's Diluted EPS for the fiscal year that ended in Dec. 2021 is calculated as

Diluted EPS (A: Dec. 2021 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-30.117-0)/19.221
=-1.57

Albireo Pharma's Diluted EPS for the quarter that ended in Sep. 2022 is calculated as

Diluted EPS (Q: Sep. 2022 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-38.178-0)/19.655
=-1.94

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Albireo Pharma  (FRA:BDQM) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Albireo Pharma EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Albireo Pharma's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Albireo Pharma (FRA:BDQM) Business Description

Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines